Department of Urology, Erzincan University Medical Faculty, Erzincan, Turkey.
Department of Urology, Amasya University Medical Faculty, Amasya, Turkey.
Aging Male. 2020 Mar;23(1):59-65. doi: 10.1080/13685538.2019.1578741. Epub 2019 Mar 12.
Benign prostatic hyperplasia (BPH) and prostate cancer (PCa) are the most common benign and malignant diseases of the prostate gland. The clinical distinction between BPH and PCa should be determined to guide patients to appropriate treatment. We aimed to evaluate the value of PSA, prostate volume (PV) and associated parameters for the detection of PCa in patients with PSA levels of 2.5-30.0 ng/mL. A total of 211 men with a biopsy (≥10 cores) and a PSA of 2.5-30.0 ng/ml were included in the study. To evaluate the performance of PV in diagnosing PCa, subjects were divided into PSA 2.5-10.0 ng/ml and PSA 10.1-30.0 ng/ml groups. Age, BMI, PSA, PV, f/t PSA, PSAD, and biopsy Gleason score were included in the analysis. PCa was diagnosed in 74 (35.1%) of the 211 patients. The differences in f/t PSA, PV, and PSAD for patients with and without PCa were statistically significant. ( < .001). PV was a significantly better indicator of PCa than PSAD and f/t PSA ratio in both groups. PV plays an active role in predicting PCa in patients with PSA in gray-zone as well as in patients with PSA 10.1-30 ng/mL.
良性前列腺增生（BPH）和前列腺癌（PCa）是前列腺最常见的良性和恶性疾病。应确定 BPH 和 PCa 之间的临床区别，以指导患者进行适当的治疗。我们旨在评估 PSA、前列腺体积（PV）和相关参数在 PSA 水平为 2.5-30.0ng/ml 的患者中检测 PCa 的价值。共有 211 名接受活检（≥10 个核心）和 PSA 为 2.5-30.0ng/ml 的男性患者纳入本研究。为了评估 PV 在诊断 PCa 中的性能，将受试者分为 PSA 2.5-10.0ng/ml 和 PSA 10.1-30.0ng/ml 组。分析包括年龄、BMI、PSA、PV、f/tPSA、PSAD 和活检 Gleason 评分。在 211 名患者中，74 名（35.1%）诊断为 PCa。有和无 PCa 患者之间的 f/tPSA、PV 和 PSAD 差异具有统计学意义（ < .001）。在两组中，PV 均比 PSAD 和 f/tPSA 比值更好地指示 PCa。PV 在 PSA 灰区患者和 PSA 10.1-30ng/ml 患者中均积极预测 PCa。
